The Prevalence of Antibodies to Adenovirus Serotype 5 in an Adult Indian Population and Implications for Adenovirus Vector Vaccines

被引:39
作者
Pilankatta, Rajendra [1 ]
Chawla, Tanu [1 ]
Khanna, Navin [1 ]
Swaminathan, Sathyamangalam [1 ]
机构
[1] Int Ctr Genet Engn & Biotechnol, Recombinant Gene Prod Grp, New Delhi 110067, India
关键词
adenovirus; adenoviral vaccine; prior adenovirus immunity; CAR; Fc receptor; NEUTRALIZING ANTIBODIES; GENE-TRANSFER; IMMUNE-RESPONSES; RHESUS-MONKEYS; CELL-LINE; REPLICATION; IMMUNOGENICITY; VIRUS; INDUCTION; INFECTION;
D O I
10.1002/jmv.21721
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
In vivo gene delivery using human adenovirus serotype 5 (AdV5) vectors is being explored for vaccination purposes. The presence of anti-AdV5 antibodies in human serum arising from natural exposure to AdV5 can interfere potentially with and compromise the efficacy of rAdV5-based vaccine vectors. In this report, a collection of 114 sera from healthy adult Indian blood donors was analyzed for the presence of anti-AdV5 antibodies, using an AdV5 vector encoding the green fluorescent protein (GFP) to monitor the presence of anti-AdV5 neutralizing antibodies in human sera based on their ability to block virus entry into HeLa cells which express the Coxsackievirus- and-Adenovirus Receptor (CAR). In this assay all samples tested were positive for anti-AdV5 antibodies, with titers varying over a very wide range. It was also observed that these antibodies facilitated the uptake of the reporter AdV5 vector into the monocytic cell line U937 which does not express CAR, but expresses Fc receptors (FcRs) instead. These observations have implications for rAdV5-based vaccine development. J. Med. Virol. 82:407-414,2010. (C) 2010 Wiley-Liss, Inc.
引用
收藏
页码:407 / 414
页数:8
相关论文
共 53 条
[1]   Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D [J].
Abbink, Peter ;
Lemckert, Angelique A. C. ;
Ewald, Bonnie A. ;
Lynch, Diana M. ;
Denholtz, Matthew ;
Smits, Shirley ;
Holterman, Lennart ;
Damen, Irma ;
Vogels, Ronald ;
Thorner, Anna R. ;
O'Brien, Kara L. ;
Carville, Angela ;
Mansfield, Keith G. ;
Goudsmit, Jaap ;
Havenga, Menzo J. E. ;
Barouch, Dan H. .
JOURNAL OF VIROLOGY, 2007, 81 (09) :4654-4663
[2]   Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene:: Application in epidemiologic studies and in the design of adenovector vaccines [J].
Aste-Amézaga, M ;
Bett, AJ ;
Wang, FB ;
Casimiro, DR ;
Antonello, JM ;
Patel, DK ;
Dell, EC ;
Franlin, LL ;
Dougherty, NM ;
Bennett, PS ;
Perry, HC ;
Davies, ME ;
Shiver, JW ;
Keller, PM ;
Yeager, MD .
HUMAN GENE THERAPY, 2004, 15 (03) :293-304
[3]   Development of nonhuman adenoviruses as vaccine vectors [J].
Bangari, DS ;
Mittal, SK .
VACCINE, 2006, 24 (07) :849-862
[4]   Rational design of gene-based vaccines [J].
Barouch, DH .
JOURNAL OF PATHOLOGY, 2006, 208 (02) :283-289
[5]   Adenovirus vector-based vaccines for human immunodeficiency virus type 1 [J].
Barouch, DH ;
Nabel, GJ .
HUMAN GENE THERAPY, 2005, 16 (02) :149-156
[6]   Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity [J].
Barouch, DH ;
Pau, MG ;
Custers, JHHV ;
Koudstaal, W ;
Kostense, S ;
Havenga, MJE ;
Truitt, DM ;
Sumida, SM ;
Kishko, MG ;
Arthur, JC ;
Korioth-Schmitz, B ;
Newberg, MH ;
Gorgone, DA ;
Lifton, MA ;
Panicali, DL ;
Nabel, GJ ;
Letvin, NL ;
Goudsmit, J .
JOURNAL OF IMMUNOLOGY, 2004, 172 (10) :6290-6297
[7]   Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 [J].
Bergelson, JM ;
Cunningham, JA ;
Droguett, G ;
KurtJones, EA ;
Krithivas, A ;
Hong, JS ;
Horwitz, MS ;
Crowell, RL ;
Finberg, RW .
SCIENCE, 1997, 275 (5304) :1320-1323
[8]   Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene [J].
Casimiro, DR ;
Chen, L ;
Fu, TM ;
Evans, RK ;
Caulfield, MJ ;
Davies, ME ;
Tang, A ;
Chen, MC ;
Huang, LY ;
Harris, V ;
Freed, DC ;
Wilson, KA ;
Dubey, S ;
Zhu, DM ;
Nawrocki, D ;
Mach, H ;
Troutman, R ;
Isopi, L ;
Williams, D ;
Hurni, W ;
Xu, Z ;
Smith, JG ;
Wang, S ;
Liu, X ;
Guan, LM ;
Long, R ;
Trigona, W ;
Heidecker, GJ ;
Perry, HC ;
Persaud, N ;
Toner, TJ ;
Su, Q ;
Liang, XP ;
Youil, R ;
Chastain, M ;
Bell, AJ ;
Volkin, DB ;
Emini, EA ;
Shiver, JW .
JOURNAL OF VIROLOGY, 2003, 77 (11) :6305-6313
[9]   Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector [J].
Catanzaro, Andrew T. ;
Koup, Richard A. ;
Roederer, Mario ;
Bailer, Robert T. ;
Enama, Mary E. ;
Moodie, Zoe ;
Gu, Lin ;
Martin, Julie E. ;
Novik, Laura ;
Chakrabarti, Bimal K. ;
Butman, Bryan T. ;
Gall, Jason G. D. ;
King, C. Richter ;
Andrews, Charla A. ;
Sheets, Rebecca ;
Gomez, Phillip L. ;
Mascola, John R. ;
Nabel, Gary J. ;
Graham, Barney S. .
JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (12) :1638-1649
[10]   Adenovirus-vectored vaccines [J].
Chawla, Tanu ;
Khanna, Navin ;
Swaminathan, Sathyamangalam .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (03) :293-307